Evidence map›Paper›PMID 30017792›Full record

Observational studyInternational journal of radiation oncology, biology, physics2018

Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.

Stephanie Dorta-Estremera, Lauren E Colbert, Sita S Nookala, Ananta V Yanamandra, Guojun Yang, Andrea Delgado, Megan Mikkelson, Patricia Eifel, Anuja Jhingran, Lin L Lilie and 4 more

Registry-linked trialOpen access · greenAbstract readObservational Study
In one paragraph

Observational study in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06686043 (A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06686043 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers

TypeinterventionalSponsorBaylor College of MedicineRan2024 to 2028Enrolled85ConditionsCervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated CarcinomaArmsHPV vaccine, Imiquimod, and metformin combination therapy
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Modulation of CD8International journal of molecular sciences · 2023
    Review
  8. Article
  9. Review
  10. Article
  11. Influence of chemoradiation on the immune microenvironment of cervical cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?International journal of molecular sciences · 2022
    Review
  18. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Stephanie Dorta-EstremeraDepartment of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Lauren E ColbertDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Sita S NookalaDepartment of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Ananta V YanamandraDepartment of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Guojun YangDepartment of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Andrea DelgadoDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Megan MikkelsonDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Patricia EifelDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Anuja JhingranDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Lin L LilieDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
James WelshDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Kathleen SchmelerDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Jagannadha K SastryDepartment of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Ann KloppDepartment of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address: aklopp@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeRadiation therapy has direct cytotoxic effects on tumor-infiltrating lymphocytes, but it also has immune stimulatory effects that increase immune cell infiltration. The dynamics of these competing effects on immune cells at the site of the tumor are poorly characterized during chemoradiation treatment (CRT) because of the difficulty of obtaining consecutive tumor biopsies. We used a minimally invasive cervical cytobrushing method to analyze the kinetics of intratumoral immune cell changes in patients with cervical cancer during CRT. METHODS AND MATERIALS: Cervical brushings were obtained from 20 patients with cervical cancer at baseline and during fractionated radiation therapy and cisplatin (weeks 1, 3, and 5). Matching peripheral blood mononuclear cells were obtained from 9 patients at the same time points. Cells were analyzed using multispectral flow cytometry to identify T cell and myeloid cell subsets and their activation status. Changes in immune cell subsets throughout treatment were calculated using matched-pair analysis with Wilcoxon rank sum test.

resultsWe observed a significant decline in CD3+ total T cells, as well as CD8+ and CD4+ T-cell subsets in the first week of treatment from baseline, followed by variable expansion at weeks 3 and 5. This coincided with higher levels of proliferating CD8+ T cells expressing Ki67 at week 3 of treatment. The percentages of activated CD8+ T cells expressing CD69 continuously increased over the course of treatment, whereas the percentage of activated CD11c+CD11b- dendritic cells was highest during the first week. Many of these changes were not observed in the blood.

conclusionsOur results identified immune dynamic changes during CRT, indicating that CRT may be immune activating at the site of the tumor. This study also suggests the importance of sequential analyses of the local tumor microenvironment in addition to peripheral blood.

Indexed as

ChemoradiotherapyImmune SystemImmunotherapyAdultAgedBiopsyCD11b AntigenCD11c AntigenCD3 ComplexCD8-Positive T-LymphocytesCell ProliferationCervix UteriDendritic CellsFemaleFlow CytometryHumansCD11b AntigenCD11c AntigenCD3 ComplexITGAM protein, humanReceptors, Antigen, T-Cell

Identifiers

PMID30017792
PMCPMC6721616
OpenAlexW2883440009

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.